JP Morgan Put 930 REGN 17.05.2024/ DE000JK0U881 /
| 2024-05-10 2:07:05 PM | Chg.- | Bid9:30:13 AM | Ask9:30:13 AM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.006EUR | - | 0.005 Bid Size: 1,000 |
0.110 Ask Size: 1,000 |
Regeneron Pharmaceut... | 930.00 USD | 2024-05-17 | Put |
GlobeNewswire
7:00 AM
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
05-10
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
05-09
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...
GlobeNewswire
05-08
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire
05-07
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
GlobeNewswire
04-29
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire
04-25
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire
04-24
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...
GlobeNewswire
04-23
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire
04-22
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...
GlobeNewswire
04-18
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...
GlobeNewswire
04-18
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Beh...
GlobeNewswire
04-16
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
GlobeNewswire
04-16
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
GlobeNewswire
04-15
Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation
GlobeNewswire
04-11
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Phar...
GlobeNewswire
04-07
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...
GlobeNewswire
04-01
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...
